

## COMPLETE LISTING OF THE CLAIMS

1. (Previously Presented) An oral dosage form comprising:  
a formulation that, upon exposure to an aqueous environment, forms a network within the formulation and an outer surface, wherein the formulation comprises:  
a drug;  
about 30 – 90 weight percent of sucrose acetate isobutyrate (SAIB) as a high viscosity liquid carrier material (HVLCM);  
a network former;  
a rheology modifier selected from the group consisting of isopropyl myristate (IPM), ethyl oleate, triethyl citrate, dimethyl phthalate, benzyl benzoate, and a caprylic/capric triglyceride; and  
a solvent, wherein said formulation provides for release of the drug over a prolonged period of time of at least an hour and is resistant to drug extraction using ethanol.

2 - 79. (Canceled)

80. (Previously Presented) The dosage form of claim 1, wherein the formulation comprises from 1 – 8.6 weight percent of the network former.

81. (Previously Presented) The dosage form of claim 80, wherein the network former comprises cellulose acetate butyrate (CAB).

82. (Previously Presented) The dosage form of claim 1, wherein the drug is selected from the group consisting of opioids, CNS depressants, and stimulants.

83. (Previously Presented) The dosage form of claim 1, wherein the formulation comprises from 20 – 50 weight percent of the solvent.

84. (Previously Presented) The dosage form of claim 83, wherein the solvent is selected from the group consisting of ethyl lactate (EL), triacetin, dimethyl sulfoxide (DMSO), propylene carbonate, N-methylpyrrolidone (NMP), ethyl alcohol, benzyl alcohol, glycofurol, alpha-tocopherol, isopropyl alcohol, diethyl phthalate, polyethylene glycol 400 (PEG 400), triethyl citrate, benzyl benzoate, and a caprylic/capric triglyceride.